Johnson & Johnson Starts New Late Stage COVID-19 Vaccine Trial

The video discusses the testing of an A2 dose regimen for an experimental COVID-19 vaccine, focusing on the potential benefits of a second dose. The study aims to include up to 30,000 participants, while a previous A1 dose trial involved around 60,000 people. Additionally, Pfizer and BioNTech reported that their vaccine showed an efficacy rate of over 90%.

What is the focus of the A2 dose regimen testing?

• To test a new vaccine for influenza

• To study the effects of a placebo

• To evaluate a single-dose COVID-19 vaccine

• To test the A2 dose regimen of an experimental COVID-19 vaccine

What is the primary goal of the study involving the second dose?

• To reduce the number of participants

• To explore the potential benefits of a second dose

• To increase the dosage of the first dose

• To test a new vaccine for another virus

How many participants are planned for the new study?

• 30,000

• 20,000

• 40,000

• 10,000

How many participants were involved in the A1 dose trial?

• 75,000

• 30,000

• 45,000

• 60,000

What effectiveness rate did Pfizer and BioNTech's vaccine show?

• 80%

• 90%

• 70%

• 95%